These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36710848)

  • 1. Government innovation subsidy, executives' academic capital and innovation quality: Evidence from pharmaceutical companies in China.
    Xia Y; Fan M; Zuo X; Hao W; Jia Y
    Front Psychol; 2022; 13():1092162. PubMed ID: 36710848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Executive pharmaceutical background, R&D investment and corporate innovation performance.
    Zhang L; Li S; Wu M
    Am J Transl Res; 2023; 15(11):6576-6586. PubMed ID: 38074834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Celebrity CEOs and firm innovation investment: Evidence from Chinese-listed companies.
    Shao D; Lv K; Zhao S; Wang S
    Front Psychol; 2022; 13():978946. PubMed ID: 36478933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Employee equity incentive, executive psychological capital, and enterprise innovation.
    Yu L; Hu J
    Front Psychol; 2023; 14():1132550. PubMed ID: 36923141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the impact mechanism of executives' environmental attention on corporate green transformation: evidence from the textual analysis of Chinese companies' management discussion and analysis.
    Ding X; Xu Z; Petrovskaya MV; Wu K; Ye L; Sun Y; Makarov VM
    Environ Sci Pollut Res Int; 2023 Jul; 30(31):76640-76659. PubMed ID: 37237116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of government subsidies on innovation of Chinese biopharmaceutical firms: Based on kink threshold model.
    Li Q; Di J; Liu Q
    Front Public Health; 2023; 11():1087830. PubMed ID: 36908409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Financial constraints, government subsidies, and corporate innovation.
    Li Q; Wang J; Cao G; Zhang J
    PLoS One; 2021; 16(11):e0259642. PubMed ID: 34758030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Research on the Effect of Executive Incentive Institutional Innovation on the Cost of Equity-Evidence From Chinese Listed Companies.
    Wang J; Deng J
    Front Psychol; 2021; 12():686955. PubMed ID: 34168600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulating CEO pay and green innovation: moderating role of social capital and government subsidy.
    Li Q; Maqsood US; Zahid RMA; Anwar W
    Environ Sci Pollut Res Int; 2024 Jul; 31(34):46163-46177. PubMed ID: 36997792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of industry-university-research projects on biopharmaceutical companies' innovation performance: moderating roles of government subsidies for innovation.
    Xia Y; Jia Y
    Front Public Health; 2023; 11():1271364. PubMed ID: 38035308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The asymmetric influences of environmental subsidy and non-environmental subsidy on corporate environmental responsibility: evidence from China.
    Wu J; Chen Z
    Environ Sci Pollut Res Int; 2022 Nov; 29(51):77057-77070. PubMed ID: 35676572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why do Chinese enterprises make imitative innovation?-An empirical explanation based on government subsidies.
    Song F; Zhao C
    Front Psychol; 2022; 13():802703. PubMed ID: 36172242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Senior executive characteristics: Impact on ESG practices and corporate valuation relationship.
    Cai C; Geng Y; Yang F
    PLoS One; 2024; 19(7):e0303081. PubMed ID: 38990983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corporate financialization, financing constraints, and innovation efficiency-Empirical evidence based on listed Chinese pharmaceutical companies.
    Zhu J; Tang Y; Wei Y; Wang S; Chen Y
    Front Public Health; 2023; 11():1085148. PubMed ID: 37124778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research on the mechanism of government subsidy on enterprise innovation based on industry-university-research collaboration.
    Zhao K; Yue D; Liu Y; Shan H
    Heliyon; 2024 May; 10(9):e30153. PubMed ID: 38694064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Returnee Executives, Corporate Social Responsibility, and Stock Price Synchronicity.
    Gao D; Zhao Y; Tian Q
    Front Psychol; 2022; 13():950436. PubMed ID: 35911051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of senior executives' overseas experience on corporate green innovation.
    Cheng F; Kuang X
    PLoS One; 2024; 19(5):e0296716. PubMed ID: 38696492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How do executives' synergistic allocation and organizational slack drive enterprise technological innovation?
    Bai G; Zhao J; Xu P
    PLoS One; 2022; 17(10):e0276022. PubMed ID: 36227881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How Labor Costs Affect Innovation Output in Pharmaceutical Companies: Evidence from China.
    Chen Y; He Q; Wang T
    Inquiry; 2024; 61():469580241246965. PubMed ID: 38726640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Turnover at the Top: The Digital Transformation and Dismissal of Chairman and CEO.
    Qi J; Zhou Y; Lv W; Du Q; Liu R; Liu C
    Front Psychol; 2022; 13():883192. PubMed ID: 35586233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.